The study is said to be the first to demonstrate efficacy for FcRn inhibition in SLE.

Reduced flare rates and immune marker improvements: In other findings presented at EULAR 2026, improvements in immunological markers and reduced flare rates were observed, supporting the potential of ...

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following ...

New trial data with Johnson & Johnson's nipocalimab, Biogen and UCB's dapirolizumab pegol, and Merck KGaA's enpatoran have ...

Among hospitalized patients with systemic lupus erythematosus, NSSTTA was identified as an independent risk factor for MACCE.

Johnson & Johnson (NYSE: JNJ) today announced nipocalimab met the primary endpoint of decreasing disease activity at 24 weeks as measured by SLE Responder Index 4 (SRI-4)b and continued to demonstrate ...

For the first time in decades, targeted therapies to treat cutaneous lupus erythematosus are advancing through the research pipeline, driven by both dermatologic and rheumatologic advancements, ...

Background Systemic lupus erythematosus (SLE) shows marked heterogeneity in epidemiology across regions and over time.

In a new study, systemic lupus erythematosus (SLE) disease severity indicated by the presence of lupus nephritis, (LN, lupus-related kidney disease) and other SLE risk factors contributed to reduced ...